Author: Michael Weaver

Journal Articles Citing CryoStor CS10® Recently Added to BioLife Solutions’ Evidence Library

Michael Weaver

Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in CryoStor CS10. An expanded list of cell types biopreserved in BioLife…

Read More

Journal Articles Citing Cryopreservation Component Recently Added to BioLife Solutions’ Evidence Library

Michael Weaver

Cryopreservation adds flexibility to timelines when working with cells. In the case of cellular therapies, that can mean initial flexibility to schedule patient cell collection, transport cells to the manufacturing facility and initiate manufacturing. Cryopreservation of the final cell therapy product adds flexibility to be able to schedule the return of cells to the patient…

Read More

Joining Forces!

Michael Weaver

BioLife Solutions issued a press release August 8, 2019, announcing the execution of a share exchange agreement to purchase the remaining 56% of shares of SAVSU Technologies that BioLife did not previously own. BioLife’s relationship with Savsu spans six years, during the development and growth of the evo® Cold Chain 2.0™ system, encompassing evo® hardware…

Read More

Could not attend? BioLife Solutions’ Posters Presented During ISCT 2019 International Meeting in Melbourne

Michael Weaver

Posters presenting data for T-cells cryopreserved in CryoStor® cryopreservation solution, authored by BioLife Solutions’ Alireza Abazari, Ph.D., Scientific Applications Director and Aby J. Mathew, Ph.D., Senior Vice President & Chief Technology Officer, were featured during the International Society for Cell & Gene Therapy meeting in Melbourne, Australia, May 29 – June 1, 2019. View the…

Read More

TrakCel and Quick Partnering Solution

Michael Weaver

According to data provided by the Alliance for Regenerative Medicine, there are nearly 900 companies responsible for more than 1000 industry-sponsored clinical trials within regenerative medicine utilizing advanced therapeutics including cell, gene, and tissue engineered products. Maintaining oversight on these precious therapies, literally vein-to-vein, encompassing a multitude of stakeholders, lengthy timelines, across countries and continents…

Read More

BioPreservation Blog 1/30/2019

Michael Weaver

Disease models facilitate understanding the pathogenesis of disease, identification and development of potential interventions and evaluation of new treatments. BioLife Solutions maintains an online, searchable, Evidence Library that contains over 365 articles, abstracts and posters citing Biopreservation efficacy of CryoStor® and HypoThermosol®. Recently added to the Evidence Library, the journal article authored by Xinyue Bai…

Read More

BioPreservation Blog 12/20/18

Michael Weaver

One of the benefits of cryopreserving cells is the flexibility in scheduling for later use that freezing provides. Determining the optimal solution for cryopreservation that consistently results in post-thaw recovery of the greatest number of highly viable, functional cells is crucial. The article by Sara S. Parker et al. published in eNeuro and recently added…

Read More

MSCs Featured in Recent Journal Articles Adds to BioLife’s Growing Evidence Library

Michael Weaver

Mesenchymal Stem Cells have been the cell type of interest for the following articles recently entered into BioLife’s growing Evidence library. 1. Sutton, M. T., Kaur, S., Brown, K. S., Skiles, M. L., Folz, M. A., Caplan, A. I. and Bonfield, T. L.. (2018). Anti-Inflammatory Therapeutic Development and Optimization of Umbilical Cord Tissue Derived Mesenchymal…

Read More